A groundbreaking discovery in the field of medicine has the potential to revolutionize the treatment of liver disease and offer hope to millions of patients. The development of a new drug, EVT0185, has shown remarkable results in reversing liver fibrosis, a dangerous condition that often leads to cancer and other severe complications.
Researchers at McMaster University, in collaboration with Espervita Therapeutics, have been leading the charge in preclinical studies for this innovative drug candidate. Their findings, published in the journal Cell Metabolism, highlight a critical gap in current treatment options for liver disease, especially in Canada, where no approved drugs exist.
Liver fibrosis is a late-stage symptom of metabolic dysfunction-associated steatohepatitis (MASH), a disease commonly associated with obesity and metabolic conditions like type 2 diabetes. It can lead to cancer, increase the risk of heart attacks and strokes, and even necessitate liver transplantation. Despite the severity of these outcomes, treatment options for MASH and other liver diseases have been limited, leaving a significant unmet need.
"The current treatment paradigm can slow the progression of liver disease, but it often fails to reverse the damage caused by fibrosis," explains Professor Greg Steinberg, lead author of the research and an executive member of NexusHealth at McMaster. "Our new drug candidate, however, shows promise in doing exactly that."
In a collaborative study with researchers from the United States, France, and Australia, Steinberg's team demonstrated the powerful effects of a novel small-molecule therapy in disease models. The drug candidate, developed by Espervita Therapeutics where Steinberg serves as chief scientific officer, shareholder, and co-founder, is being further evaluated through a research partnership with McMaster University.
Scientists have shown that EVT0185 can control blood sugar levels, reduce cholesterol, and eliminate the fat buildup that causes liver fibrosis. This compound was initially described as a potential treatment for liver cancer due to its promising anti-tumor activity, published in the journal Nature. While its potential as a cancer therapeutic remains, this recent discovery expands its horizon as a treatment option for MASH.
"The need for agents that reduce liver fibrosis and improve blood glucose and cholesterol levels is immense," says Steinberg, co-director of the Centre for Metabolism, Obesity, and Diabetes Research at McMaster. "This drug candidate fills a significant therapeutic gap and has the potential to transform the way we treat severe liver disease, preventing liver cancer and other complications like diabetes and heart disease."
The new small molecule works by targeting two critical enzymes, ACLY and ACSS2, which control fat synthesis and burning. Steinberg describes it as a "carbon release valve" in the body, preventing harmful matter from accumulating in the liver and bloodstream and instead eliminating it through urine.
With clinical trials expected to begin in 2027, pending final preclinical and toxicology work, this development offers a glimmer of hope for those living with liver disease. The study was supported by funding from Espervita Therapeutics, the Canadian Institutes of Health Research, MITACS, and McMaster University.
But here's where it gets controversial: While this drug shows promise, it's important to remember that it's still in the early stages of development. What are your thoughts on the potential of this drug? Do you think it could be a game-changer in the treatment of liver disease? We'd love to hear your opinions in the comments below!
